Lundbeck and Otsuka Pharmaceutical Co announced that the FDA approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of...
The FDA has accepted for review a supplemental New Drug Application (sNDA) for the proposed labeling update of Rexulti (brexpiprazole),...
Health Canada has approved Rexulti (brexpiprazole) for agitation associated with Alzheimer’s disease-related dementia in patients with aggressive behavior
Otsuka Pharmaceutical Co and Lundbeck announced study results on the safety and efficacy of Rexulti (brexpiprazole) in the treatment of...
Otsuka Pharmaceutical has filed its antipsychotic agent Rexulti (brexpiprazole) in Japan for a label expansion into agitation associated with dementia due to Alzheimer’s disease
Otsuka Pharmaceutical/Lundbeck’s atypical antipsychotic Rexulti (brexpiprazole) has secured the recommendation of two FDA advisory committees - the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee which at their joint meeting voted 9-1 that Otsuka and Lundbeck provided sufficient data to identify an AAD population in whom the benefits of the drug outweigh its risks for its label expansion
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the FDA has approved the supplemental New Drug Application (sNDA) of Rexulti (brexpiprazole) for use in the treatment of agitation associated with dementia due to Alzheimer’s disease.
Lundbeck and Otsuka announced that the FDA has approved the labeling update of Rexulti (brexpiprazole) to reflect clinical data for...